会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 49. 发明申请
    • Engraftable neural progenitor and stem cells for brain tumor therapy
    • 可植入神经祖细胞和干细胞用于脑肿瘤治疗
    • US20050169897A1
    • 2005-08-04
    • US10947407
    • 2004-09-22
    • Evan SnyderKaren AboodyXandra BreakefieldWilliam Lynch
    • Evan SnyderKaren AboodyXandra BreakefieldWilliam Lynch
    • A61K35/12A61K38/12C12N5/0797C12N5/10A61K48/00C12N5/08
    • C12N7/00A61K35/12A61K38/00A61K48/0008A61K48/0075C12N5/0623C12N15/86C12N2510/00C12N2710/16052C12N2710/16643C12N2740/10052Y02A50/473
    • One of the impediments to the treatment of some human brain tumors (e.g. gliomas) has been the degree to which they expand, migrate widely, and infiltrate normal tissue. We demonstrate that a clone of multipotent neural progenitor stem cells, when implanted into an experimental glioma, will migrate along with and distribute themselves throughout the tumor in juxtaposition to widely expanding and aggressively advancing tumor cells, while continuing to express a foreign reporter gene. Furthermore, drawn somewhat by the degenerative environment created just beyond the infiltrating tumor edge, the neural progenitor cells migrate slightly beyond and surround the invading tumor border. When implanted at a distant sight from the tumor bed (e.g., into normal tissue, into the contralateral hemisphere, into the lateral ventricles) the donor neural progenitor/stem cells will migrate through normal tissue and specifically target the tumor cells. These results suggest the adjunctive use of neural progenitor/stem cells as a novel, effective delivery vehicle for helping to target therapeutic genes and vectors to invasive brain tumors that have been refractory to treatment.
    • 治疗某些人脑肿瘤(例如神经胶质瘤)的障碍之一是它们扩张,迁移广泛并渗透正常组织的程度。 我们证明,当植入实验性神经胶质瘤时,多潜能神经祖细胞的克隆将与整个肿瘤一起迁移并分布在整个肿瘤中,并与广泛扩张和积极进展的肿瘤细胞并列,同时继续表达外源报告基因。 此外,由于刚刚超出渗透性肿瘤边缘的退化环境,神经祖细胞迁移稍微超出并包围入侵肿瘤边界。 当植入远离肿瘤床(例如,进入正常组织,进入对侧半球,进入侧脑室)时,供体神经祖细胞/干细胞将迁移通过正常组织并且特异性靶向肿瘤细胞。 这些结果表明辅助性使用神经祖细胞/干细胞作为一种新型有效的递送载体,用于帮助将治疗基因和载体靶向治疗难治性的侵袭性脑肿瘤。